News for BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals Inc (BCRX) announced its financial results for the fourth quarter and full year ending December 31, 2024, on February 24, 2025. The com

ORLADEYO Revenue Growth: 34% year-over-year increase for 2024.Total Revenue for Q4 2024: $131.5 million.ORLADEYO Revenue for Q4 2024: $124.2 million.Total Reve

Feb 24, 2025 / 01:30PM GMTOperator Good day and welcome to the BioCryst fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode. (Operat

The following slide deck was published by BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ETCompany ParticipantsJohn Bluth - Chief...

BioCryst Pharmaceuticals, Inc. (BCRX) posted a net loss for the fourth quarter of $26.8 million, or $0.13 per share, compared to a net loss of $61.7 million, or $0.

BioCryst (BCRX) delivered earnings and revenue surprises of -116.67% and 0.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

””ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)”” ””FY 2025 ORLADEYO net rev

Revenue: $131.5 million for Q4 2024, surpassing the estimated $130.15 million, marking a 40.8% increase year-over-year.ORLADEYO Net Revenue: $124.2 million for

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On February 12, 2025, BioCryst Pharmaceuticals Inc (BCRX) announced that Infarmed, the Portuguese National Authority of Medicines and Health Products, has recom

**media[538607]**

Summary BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company specializing in treatments for rare diseases, announced that it will release its fou

**media[536536]**

**media[531545]**

Summary BioCryst Pharmaceuticals Inc (BCRX) announced its preliminary, unaudited financial results for the fourth quarter and full year 2024, alongside its proj

””ORLADEYO net revenue expected to be between $515-$535 million in 2025”” ””Total revenue (including RAPIVAB®) expected to be between $540-$560 million in

**media[511553]**

BioCryst projects $515-$535 million in ORLADEYO sales for 2025